Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDEAL: Anti-CD19 CAR-T in Refractory ANCA Vasculitis
2024-517303-36-00Phase 2Authorised
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Dec 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mivocabtagene autoleucel in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoints: Incidence and grading of CRS and ICANS within 4 weeks, Safety over entire study and 1 more. Planned start Dec 2024; status: authorised.
02
Drugs
mivocabtagene autoleucel
03
Conditions
granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on 2024-517303-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517303-36-00.